EDITEditas Medicine, Inc.

$256M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$61,000-98.9% YoY

Gross Profit

-$2M-2521.3% margin

Operating Income

-$66M-107649.2% margin

Net Income

-$62M-101870.5% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

-88.1%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$56M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$328M

Total Liabilities

$152M

Stockholders' Equity

$176M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61,000	$5M	-98.9%
Gross Profit	-$2M	$4M	-140.2%
Operating Income	-$66M	-$50M	-30.9%
Net Income	-$62M	-$45M	-38.0%

EDIT Q3 2024 Earnings — Editas Medicine, Inc. Revenue & Financial Results | Market Cap Arena